Trial evaluating the efficacy and the safety of FOLFIRINOX3 treatment in patients with unresectable locally advanced or metastatic pancreatic cancer in first line of chemotherapy

2023-505889-29-01 Protocol FOLFIRINOX3_PANCREAS Therapeutic exploratory (Phase II) Ongoing, recruiting

Start 1 Feb 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 4 sites · Protocol FOLFIRINOX3_PANCREAS

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Ongoing, recruiting
Participants planned 90
Countries 1
Sites 4

Patients with unresectable locally advanced or metastatic pancreatic cancer in first line of chemotherapy

Key facts

Sponsor
Centr Georges Francois Leclerc
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
1 Feb 2024 → ongoing
Decision date (initial)
2023-10-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with unresectable locally advanced or metastatic pancreatic cancer in first line of chemotherapy

VersionLevelCodeTermSystem organ class
21.0 LLT 10033606 Pancreatic cancer non-resectable 10029104
21.1 LLT 10033605 Pancreatic cancer metastatic 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centr Georges Francois Leclerc

Sponsor organisation
Centr Georges Francois Leclerc
Address
1 Rue Professeur Marion
City
Dijon
Postcode
21000
Country
France

Scientific contact point

Organisation
Centr Georges Francois Leclerc
Contact name
Head of project

Public contact point

Organisation
Centr Georges Francois Leclerc
Contact name
Head of project

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 90 4
Rest of world 0

Investigational sites

France

4 sites · Ongoing, recruiting
Besancon University Hospital Center
Oncology, 3 Boulevard Alexander Fleming, Cs 81816, Besancon Cedex
Institut Godinot
Oncology, 1 Rue Du General Koenig, 51100, Reims
Centr Georges Francois Leclerc
Oncology, 1 Rue Professeur Marion, 21000, Dijon
Hopital Prive Sainte Marie Chalon
Oncologie, 4 Allee De Saint Jean Des Vignes, 71100, Chalon Sur Saone

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-02-01 2024-02-12

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-07-20 France Acceptable
2023-10-03
2023-10-03